 |
|
|
|
 |
|
|
| Article 1 to 4 out of 4 concerning Chimera Biotec GmbH
|
-
Chimera Biotec invites scientists to the III. Immunolympics 2008
(05 Jun 2008)
For the third time Chimera Biotec supports the scientific community with a contest on ultra-sensitive immunoassays, the III. Immunolympics are open. The contest seeks to find potential solutions to today's scientific challenges using ultra-sensitive ...
-
CNS-Diagnostics: Chimera Biotec Starts Study on Novel Biomarker Detection for Alzheimer's Disease
(13 Mar 2007)
European Commission supports study including 11 centres from 6 European countries
Chimera Biotec joins the EU funded EDAR project to adapt the Imperacer(TM) platform technology for the detection of novel biomarkers for the diagnosis of Alzheimer's disease. The consortium wants to find out whether the new markers can be used to ...
-
Chimera Biotec Partners with AvTech Laboratories to Provide Ultra-High Sensitive Immunoassay Technology to U.S.
(14 Sep 2006)
AvTech Laboratories, a division of Eurofins Scientific, and Chimera Biotec GmbH have signed a cooperation agreement that combines Chimera's ultra-high sensitive immunoassay technology, Imperacer, with AvTech's expertise in state-of-the-art ...
-
1,000 times higher sensitivity for doping testing available now
(08 Feb 2006)
Chimera Biotec and German Sports University developed a new and extremely sensitive technology for anti-doping testing
Dr. Michael Adler, head of R&D at Chimera Biotec GmbH, Dortmund, Germany, and his group develop an ultra sensitive test for the detection of myostatin doping together with the team of Dr. Patrick Diel at the German Sports University, Cologne, ...
Additional information
 Chimera Biotec GmbH
Dortmund, Germany
Company
Articles
Products
|
|
|
|
|
|
Top
